Several clinical trials have been performed to study the effect of GLP-1 RAs on NAFDL and NASH since 2007, most of which concerned the determination of the role of these drugs in NAFLD and recruited individuals with pre-existing T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.